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ABSTRACT  
 
 This substudy of a large, randomized, controlled trial (NCT01072396) examined 
WLRWURSLXPȝJqd) effects on dynamic hyperinflation during constant work rate treadmill 
exercise. Areas-under-the-spontaneous expiratory flow-volume (SEFV)-curves were compared 
in 20 COPD patients and 16 age-matched untreated controls, using rectangular area ratio 
(RAR) between peak intrabreath and end-expiratory flow.  
 Seven patients exhibited SEFV curve concavity with 5$5 (RARlow) in test without 
tiotropium; (mean±SD FEV1: 1.60±0.59 L; 63.4±14.0 %predicted). In RARlow patients, tiotropium 
increased end-exercise inspiratory capacity (IC, 2.10±0.05 vs. 1.89±0.05 L, tiotropium vs. 
placebo; p=0.045) and RAR (0.57±0.02 vs. 0.53±0.02; p<0.001). Patients without SEFV curve 
concavity with RAR>0.5 (n=13; RARhigh), had higher screening FEV1 (2.15±0.47 L; 79.6±10.1 
%predicted) versus RARlow patients and no difference in end-exercise IC and RAR between 
tiotropium and placebo (IC: 2.24±0.03 vs. 2.17±0.03 L; RAR: 0.63±0.005 vs. 0.62±0.005). RAR 
and %predicted IC at peak exercise were positively correlated in RARlow patients (R2=0.43, 
p=0.0002). 
 Tiotropium increased exercise RAR in GOLD 1-2 patients with SEFV curve concavity.  
Keywords:  
Constant work rate; Dynamic hyperinflation; Expiratory flow limitation; Inspiratory capacity; 
Rectangular area ratio; Treadmill exercise 
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1. Introduction 
Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and 
morbidity, affecting millions of people worldwide (Global Initiative for Chronic Obstructive Lung 
Disease (GOLD), 2017). Currently, the accepted classification standard for grading the 
spirometric severity of COPD is set out in the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) report (Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2017), 
and is based on post-bronchodilator forced expiratory volume in 1 s (FEV1). However, this 
spirometric variable correlates poorly with clinical variables such as exercise tolerance (Puente-
Maestu et al., 2016), and may provide an oversimplified representation of COPD severity. 
It has been well recognized that there is information embedded in the spontaneous flow±
volume loop beyond that reflected in spirometric values, but the task of analyzing the geometry 
of flow±volume loop shapes in a meaningful manner remains difficult. Traditionally, expiratory 
flow limitation is said to occur when the tidal flow±volume loop encroaches on the maximal 
expiratory flow±volume curve (Johnson et al., 1999). During exercise in COPD, as hyperinflation 
develops, the elastic recoil decreases lengthening the expiratory time constants of these lung 
units, necessitates increased intrathoracic pressure to maintain flow. Greater expiratory 
pressures augment gas compression and dynamic airway compression, leading to a 
progressive fall in expiratory flow, which manifests as concavity in the spontaneous expiratory 
flow±volume (SEFV) curve (Lee et al., 2016; Ma et al., 2010; Varga et al., 2016). Expiratory flow 
limitation contributes to dynamic hyperinflation during exercise, whereby the end-expiratory lung 
volume progressively increases and inspiratory capacity (IC) and inspiratory reserve volume are 
reduced, and which is associated with dyspnea and exercise intolerance in COPD (O'Donnell et 
al., 2004). In case of these events, the following is our working hypothesis: i) the shape of the 
flow±volume loop becomes concave; ii) the concavity reflects increased airway resistance; iii) 
reduced elastic recoil in COPD (particularly in emphysema) increases expiratory time constants, 
which necessitates increased intrathoracic pressure to maintain flow; this should further worsen 
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the concavity of the flow±volume loop; iv) bronchodilation should improve this situation and, as 
such, it should reflect in analysis of the concavity of the flow±volume loop which could then be 
useful to evaluate the effects of bronchodilators. Breath-by-breath quantification of SEFV curve 
concavity has been used to describe progressive shape changes denoting expiratory flow 
limitation during incremental exercise in patients with COPD (Ma et al., 2010; Varga et al., 
2016).  
Tiotropium, a once-daily, long-acting muscarinic antagonist (LAMA) bronchodilator, 
approved for COPD management, is associated with significant improvement in lung 
hyperinflation and exercise tolerance in COPD patients with GOLD spirometric grades 2±4 
(Maltais et al., 2005; O'Donnell et al., 2004; Verkindre et al., 2006). In GOLD 1 COPD patients, 
tiotropium significantly reduced dynamic hyperinflation, but this did not translate into significant 
exercise tolerance improvement (Casaburi et al., 2014). The authors postulated this lack of 
improvement may be due to exercise limitation from leg muscle fatigue rather than from 
dyspnea. Another possibility is that there is a heterogeneous response to tiotropium within 
GOLD 1 patients. The differences in response to tiotropium between patients with GOLD 1 and 
2 COPD may represent fundamental differences in the nature and extent of abnormalities of 
peripheral airway dynamics and propensity to dynamic hyperinflation, which are directly 
explored in this current study. While the GOLD classification system broadly categorizes 
patients with COPD based on their FEV1 and FEV1/forced vital capacity (FVC), there is growing 
evidence that considerable clinical heterogeneity exists within groups with similar spirometric 
values (Gagnon et al., 2015).  
The aim of this study was to examine how tiotropium versus placebo influences the 
shape of the SEFV curve during constant work rate (CWR) treadmill exercise in patients with 
mild and moderate COPD (GOLD grades 1 and 2) and determine the association of any 
treatment-related change in the SEFV curve with change in dynamic hyperinflation.  We 
empIoyed the strategy of dividing the patient group between those who did or did not 
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demonstrate flow-volume concavity during exercise.  We reasoned that those who 
demonstrated flow-volume concavity would be more likely to respond to bronchodilation with 
reduction in dynamic hyperinflation and improvement in exercise tolerance.  
 
2. Materials and methods 
2.1 Study design 
This substudy constituted an exploratory analysis of a large multicenter trial 
(ClinicalTrials.gov identifier: NCT01072396). The main study was conducted over 22-weeks, 
and was a multicenter (11 US and four Canadian sites), randomized, double-blind, two-period, 
crossover study (Fig. 1), which assessed the effects of once-daily tiotropium vs. placebo on 
dynamic hyperinflation and exercise tolerance in patients with symptomatic GOLD 1 and 2 
COPD (Casaburi et al., 2014; O'Donnell et al., 2014). Patients who completed a 2-week 
Characterization Phase (Visits 1±3) (O'Donnell et al., 2014) and were eligible for further study 
participation were entered into the Treatment Phase (Visits 4±6) (Casaburi et al., 2014). 
Patients were randomized 1:1 to 6 weeks of 18 µg tiotropium or placebo (oral inhalation 
capsule) administered once daily via a HandiHaler® (Boehringer Ingelheim, Ingelheim, 
Germany). Following a 4-week washout, patients switched over treatments. After completion of 
the last 6-week treatment period patients were followed up for 30 days (Visit 7). Patients who 
discontinued, were followed up for 30 days after the final dose of study medication. In addition, 
a reference group of healthy, age-matched, control participants were enrolled in the 
Characterization Phase.  
The main study and the substudy were approved for all participating institutions by local 
or central Independent Review Boards and were conducted in accordance with the principles of 
the Declaration of Helsinki (October 1996) and the International Conference on Harmonisation 
Tripartite Guidelines for Good Clinical Practice. Written informed consent was obtained from all 
participants before entering the study.  
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2.2 Study participants  
The patients in this substudy were those recruited at two sites each in the US and 
Canada that were equipped for data collection for the substudy: the patients were not subjected 
to any further selection criteria. Study participants were males and females, aged 40 years, 
body mass index 18±35 kg/m2, current or ex-smokers (smoking KLVWRU\SDFN-years) with a 
post-bronchodilator FEV1/FVC <70%, and FEV1 SUHGLFWHG(Quanjer et al., 1993) at Visit 1. 
Patients were categorized according to the 2014 GOLD spirometric classification scheme 
(Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2014): GOLD grade 1 (post-
bronchodilator FEV1/FVC <0.7 and FEV1 RISUHGLFWHGDQG*2/'JUDGHSRVW-
bronchodilator FEV1)9&DQG)(91 <80% predicted). Patients were required to 
demonstrate dynamic hyperinflation during exercise manifested by a >100 mL IC decrease 
during exercise from mean resting values in two out of three baseline exercise tests (Visits 1 
through Visit 3; Fig. 1). Participants were symptomatic, as determined by a Baseline Dyspnea 
IQGH[IRFDOVFRUH(Mahler et al., 1984) and/or daily cough with production of sputum for 3 
months/year during at least two consecutive years. Patients with significant disease other than 
COPD were excluded if it was likely that the study results, patient welfare, or ability of patients 
to participate in the study would be affected. Healthy, age-matched control subjects, with normal 
lung function and minimal smoking history (i.e., no cigarettes in the preceding 2 years and <1-
pack year smoking history) participated in the Characterization Phase of the study only (Visits 
1±3).  
 
2.3 Study procedures 
During screening (±30 to ±14 days from the start of treatment) participants provided a 
medical history and demographic data, and pre-exercise pulmonary function assessed by 
spirometry. Spirometry values were obtained 60 min before the exercise tests and 80 min after 
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dosing (placebo or tiotropium). All spirometry was carried out according to American Thoracic 
Society/European Respiratory Society recommendations (Miller et al., 2005). The predicted 
values of Quanjer et al. (Quanjer et al., 1993) were used for FVC and FEV1. A symptom-limited 
treadmill incremental exercise test (IET) was performed on Visit 1 using a linearized protocol 
(Porszasz et al., 2003). To achieve an optimal exercise time between 8 and 12 min, for patients 
with COPD, the IET was carried out using a 10 W/min protocol; which was repeated at 15 
:PLQLISHDNZRUNUDWHZDV:)RUWKHFRQWURO subjects, a 15 W/min protocol was used, 
ZKLFKZDVUHSHDWHGDW:PLQLIWKHSHDNZRUNUDWHZDV:5HVXOWVRIWKH,(7ZHUH
used to set the treadmill speed and inclination for subsequent CWR tests to produce a work rate 
that was equivalent to 80% peak work rate in the IET. The target exercise duration for the CWR 
tests was 4±10 min; if this target range was not met during a practice CWR test at Visit 2, work 
rate adjustments were made for subsequent visits. One further adjustment was permitted, and 
subjects were excluded if the target duration was still not met. CWR tests were performed at 
Visits 2±6, with Visit 2 used for participant familiarization. Visits 3 and Visit 5 were baseline tests 
for the corresponding therapeutic intervals. CWR testing was performed before study drug 
administration on Visits 3 and 5, and after study drug administration on Visits 4 and 6. During 
exercise testVPLQXWHYHQWLODWLRQ9%cE) was measured breath by breath using a Vmax® Spectra, 
Version 12.2 (SensorMedics Corp., Yorba Linda, CA, USA) and was compared with indirectly 
estimated maximum voluntary ventilation (MVV), which was calculated as FEV1 × 40. IC was 
measured at rest, during warm-up (level walking at 0.8 mph for 3 min), and every 2 min during 
the exercise test and recovery; all ICs were manually checked for accuracy and, if needed, were 
adjusted to the stable end-expiratory lung volume. The IC was expressed as % predicted values 
as calculated from the predicted total lung capacity minus functional residual capacity (Stocks 
and Quanjer, 1995). 
 
2.4 Analysis of tidal flow 
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Spontaneous tidal flow was digitized using 16-bit A/D conversion at 100 Hz (National 
Instruments, Austin, TX, USA). Progressive expiratory flow limitation was quantified by 
comparing, on a breath-by-breath basis, the area under the SEFV curve relative to a rectangle 
spanning peak intrabreath and end-expiratory flow (the rectangular area ratio [RAR]) (Ma et al., 
2010). For a visual representation of the derivation of the RAR see Fig. 2 (Varga et al., 2016). 
Customized procedures were executed using IGOR software (WaveMetrics Inc., Lake Oswego, 
OR, USA) for geometric analysis of flow±volume curves. The breath-by-breath output of the 
analysis is presented from two representative subjects along with the instantaneous flow in Fig. 
3. The black lines in this figure are the result of an exponential smoothing; the corresponding 
RAR values were taken from this smooth line. As shown in Fig. 3B, the RAR initially was around 
0.6, it then gradually decreased during exercise and falling to below 0.5 towards end-exercise; 
this suggests that there is a developing concavity in the expiratory flow±volume curve. Based on 
the SEFV curve shape, the patients with COPD were categorized into two groups according to 
whether or not they exhibited concavity in the expiratory limb of the flow±volume curve during 
any of the screening incremental or baseline CWR tests (IET in Visit 1 or during Visits 2, 3, or 5 
CWR tests); the RARhigh group included COPD patients with RAR >0.5 and the RARlow group 
included COPD SDWLHQWVZLWK5$5 The actual values of RAR were taken from the curve 
resulting from an exponential smoothing, as detailed in the legend to Fig. 3. RAR was calculated 
in the control participants in the same way, as a comparator for the RARhigh and RARlow COPD 
patients. 
 
2.5 Statistical analysis 
Comparison of baseline characteristics was performed between the RARhigh and RARlow 
groups by unpaired Student t-tests, or one-way ANOVA with post hoc comparisons when 
appropriate. Most of the analyses, involving two treatment conditions and exercise levels were 
carried out by two-way repeated measures ANOVA with post hoc Holm±âtGiNPXOWLSOH
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comparisons. In those instances when the groups, treatment conditions, and exercise levels 
were simultaneously compared, we used three-way ANOVA. In these, the least square means 
and the standard error of least square means are reported. For the statistical analyses and 
graphical presentations SigmaPlot Version 13 (Systat Software, Inc., San Jose, CA) was used. 
 
3. Results 
3.1 Baseline characteristics 
$OOSDUWLFLSDQWV¶WHVWVZHUHFRPSOHWHGEHWZHHQ0DUFKDQG$XJXVW7KH
baseline demographic characteristics of the study participants are shown in Table 1. Of the 20 
patients with COPD enrolled in the study, 7 patients exhibited concavity (RARlow group) during 
at least one of the baseline exercise tests (Visit 3 and Visit 5). These patients were mainly 
GOLD 2 COPD (6 out of 7 patients [86%]) and had worse obstruction compared with patients 
without concavity (RARhigh group) on the SEFV curve of whom 31% (4 out of 13 patients) were 
categorized as GOLD 2 COPD. 
 
3.2 Effect of placebo and tiotropium treatment on spirometry 
At baseline, both the RARhigh and RARlow groups showed significantly lower FEV1 and 
FEV1/FVC than the control group (both p = 0.001), and the RARlow group had significantly worse 
spirometry data than the RARhigh group (Table 1). Compared with baseline, FEV1 tended to be 
lower in both RAR groups after placebo treatment; however, this decrease did not reach 
statistical significance in either group. Conversely, after tiotropium FEV1 increased significantly 
in both RAR groups compared with placebo (RARhigh, p = 0.004; RARlow, p = 0.038; Table 1).  
 
3.3 Initial characterization of SEFV curve and IC 
 During the baseline CWR tests, as ventilation increased, RAR responded differently in 
RARlow participants compared with RARhigh and control participants (Fig. 4A). In general, as 
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previously shown, (Ma et al., 2010; Varga et al., 2016) control subjects increase RAR during 
exercise. Similarly, RAR tended to rise in the RARhigh group as exercise progressed. In the 
RARlow group, RAR was significantly lower at rest and warm up compared with the other two 
groups, and failed to increase during exercise. ICLQFUHDVHGDVDIXQFWLRQRI9%cE/MVV with 
exercise in control subjects. In both the RARhigh and RARlow groups, IC decreased with exercise, 
with the RARlow group having lower absolute IC values throughout all stages of exercise than 
the other two groups (three-way ANOVA p < 0.001; Fig. 4B), suggesting greater dynamic 
hyperinflation. It is worth noting that the fall in IC during exercise is similar in both groups; the 
main difference is resting IC, which is lower in the RARlow group. 
 
3.4 Effect of placebo and tiotropium treatment on dynamic hyperinflation during CWR exercise  
In the RARhigh group, after both placebo and tiotropium treatment, IC significantly 
decreased during exercise (two-way repeated measures ANOVA p < 0.001 between exercise 
phases); however, there was no difference between the two treatment conditions; the IC at peak 
exercise was 2.17 ± 0.03 L vs. 2.24 ± 0.03 L for placebo vs. tiotropium (Fig. 5A). A similar 
decrease in IC during exercise was found in the RARlow group; however, after tiotropium 
treatment compared with placebo, IC was higher at all CWR test phases, with post hoc tests 
showing significance at rest, and at all exercise phases and in the first minute of recovery (all p 
< 0.05); the IC at peak exercise was 1.89 ± 0.05 L vs. 2.10 ± 0.05 L (p = 0.045) for placebo vs. 
tiotropium (Fig. 5B). In the RARlow group, but not in the RARhigh group, tiotropium was 
associated with less static hyperinflation.  
 
3.5 Effect of placebo and tiotropium treatment on RAR during CWR exercise 
As in the control subjects (Fig. 4), as exercise proceeded the expiratory limb of the 
spontaneous flow±volume curves became more convex in the RARhigh group after both placebo 
and tiotropium treatment, i.e., RAR increased (Fig. 6A; two-way repeated measures ANOVA p < 
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0.001 for exercise phases) without significant difference between the two treatment modalities. 
For the RARhigh group, RAR was 0.64 ± 0.011 and 0.65 ± 0.011 at peak exercise for placebo 
and tiotropium, respectively. As in the RARhigh group, there was a similar pattern during exercise 
in the RARlow group; however, the increase in convexity with exercise did not reach significance. 
On the other hand, after tiotropium treatment, the RAR was significantly higher than after 
placebo treatment (two-way ANOVA main effect for treatment p < 0.001) overall, during 
exercise and recovery, although post hoc comparisons did not reveal significant differences at 
any point of exercise (Fig. 6B). In the RARlow group at peak exercise RAR was 0.53 ± 0.02 and 
0.57 ± 0.02 for placebo and tiotropium, respectively (Fig. 6B). 
 
3.6 Correlation of dynamic hyperinflation and RAR at end-exercise in CWR exercise tests 
In the RARlow group, considering baseline, placebo and tiotropium tests, there was a 
significant association between RAR and % predicted IC at peak exercise (Stocks and Quanjer, 
1995) (R2 = 0.43, p = 0.0002); tests with higher IC also had higher RAR (Fig. 7). These findings 
confirm those reported by Varga et al. (Varga et al., 2016) in a more spirometrically severe 
COPD group. In contrast, the RARhigh group showed a weaker and negative correlation with IC 
% predicted (R2 = 0.22, p = 0.0004) (data not shown). 
 
3.7 Exercise endurance 
Exercise endurance of RARhigh patients was similar between the baseline, after placebo, 
and after tiotropium treatment (495 ± 187 s, 484 ± 184 s, and 487 ± 203 s, respectively). In  the 
RARlow group, two way ANOVA showed that, with respect to baseline, the change in exercise 
tolerance after placebo was -18 ± 72 s and the change after tiotropium was 68 ± 109 s; this 
difference, however, did not achieve significance (p= 0.151).  However, the difference in 
exercise tolerance after tiotropium (498 ± 227 s) differed significantly from that after placebo 
(318 ± 76 s), p=0.034, by paired t-test. 
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3.8 Ratings of Perceived Dyspnea 
The isotime Borg ratings of the perceived dyspnea before and after each therapeutic 
arm was 3.9 ± 1.4 before vs 4.9 ± 3.3 after placebo, and 3.5 ± 2.0 before vs. 3.7 ± 1.8 after 
tiotropium in the RARlow group. The same comparison in the RARhigh group was 5.9 ± 2.4 before 
and 6.3 ± 2.4 after placebo and 6.0 ± 2.1 before and 5.8 ± 2.5 after tiotropium. The changes 
follow the logical expectation, however none of these comparisons were statistically significant. 
This finding is congruent with the finding reported in the primary manuscript based on this trial 
(Casaburi et al., 2014). 
 
4. Discussion 
In healthy control subjects, the expiratory limb of the flow±volume curve is convex and 
becomes more convex on exercise. In contrast, we have observed in this study in GOLD 1 and 
2 COPD patients, that there is a subset of patients in whom the expiratory limb of the flow±
volume curve becomes less convex, and even in some cases (in 7 out of 20 patients) becomes 
concave on exercise. This might reflect increased airway resistance, which contributes to 
causing dynamic hyperinflation. In the RARlow group (i.e., those patients with concavity in the 
expiratory limb of the flow±volume curve during exercise), the main effect of tiotropium 
treatment appears to have been on resting hyperinflation: at rest (pre-exercise), IC was higher 
in the tiotropium group compared with the placebo group, and this difference between 
treatments was maintained throughout exercise and in the first minute of recovery. This 
difference was seen, however, only in patients who demonstrate concavity during exercise. In 
the RARhigh group, IC at rest and over the exercise period was similar between treatment 
groups, indicating they did not respond to tiotropium therapy and there were similar RARs 
during rest and exercise. 
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Among tests, end-exercise RAR and IC showed a significant positive correlation. This is 
the first report showing that the shape of SEFV curve responds to bronchodilator therapy in 
COPD patients who demonstrate concavity during exercise, and that this response is 
associated with less dynamic hyperinflation. Patients with concavity in the SEFV curve have 
significantly lower resting FEV1 than those without.  
LAMAs are currently recommended as first-line therapy for moderate-to-severe COPD 
(Group B, C, and D) and as second line therapy for mild COPD (Group A) as an alternative to 
short-acting bronchodilators (Global Initiative for Chronic Obstructive Lung Disease (GOLD), 
2017). However, spirometry alone is inadequate in distinguishing which patients may benefit 
from LAMA therapy. Previous studies have shown that graphical analysis of SEFV curve can be 
useful in identifying progressive expiratory flow limitation (Lee et al., 2016; Ma et al., 2010) and 
correlates better with clinical parameters, such as the 6-minute walk test distance, than do 
traditional spirometric values (Lee et al., 2016). This study is the first to investigate whether the 
SEFV curve changes with interventions that are designed to improve expiratory flow. 
The aim of this study was to utilize geometric analysis of expiratory flow±volume curves 
to discriminate between subgroups of GOLD 1 and 2 COPD patients who may have different 
airway dynamics. This study showed that a subgroup of COPD patients who exhibited some 
concavity during exercise formed a distinct phenotype that was associated with more dynamic 
hyperinflation, as shown by a smaller IC at rest and similarly smaller IC was maintained during 
exercise. Although, as compared with placebo treatment, FEV1 increased in response to 
tiotropium in all COPD patients, the change versus baseline was only significant in the RARlow 
group. This subgroup of patients with some concavity in SEFV curve at baseline had a 
statistically significant increase in RAR in response to tiotropium, while the subgroup of patients 
who did not develop SEFV curve concavity at baseline had no RAR response to tiotropium. This 
is consistent with previous reports of heterogeneity within groups of COPD patients with similar 
spirometry and reaffirms the potential benefits of an individualized approach to patient therapy 
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(Gagnon et al., 2015). The method of measuring RAR change is especially attractive due to its 
ability to characterize the profile of the expiratory flow±volume curve during spontaneous 
breathing without the need for additional ventilatory maneuvers. 
 It is worth also noting that the exercise endurance of the RARhigh patients was virtually 
insensitive to any treatment or lack thereof (495 ± 187 s, 484 ± 184 s, and 487 ± 203 s during 
baseline, after placebo, and after tiotropium treatment, respectively). On the other hand, RARlow 
patients decreased exercise endurance after placebo (338 ± 81 to 318 ± 76 s, paired t-test, not 
significant), and increased endurance after tiotropium (498 ± 227 s, paired t-test vs. placebo p = 
0.034). The difference (180 s) exceeds the minimal clinically important difference (105 s in 
training-related trials and 60 s for bronchodilator trials) established for CWR exercise tests 
(Puente-Maestu et al., 2016). In the parent study (Casaburi et al., 2014), tiotropium both 
reduced hyperinflation and increased exercise endurance in GOLD 2 COPD patients, but only 
hyperinflation was reduced in GOLD 1 COPD patients who had no change in exercise 
endurance. In this substudy, neither the IC nor exercise endurance increased in the RARhigh 
group, which was comprised mainly of GOLD 1 patients (9 out of 13). These results, suggest 
that better airway dynamics (higher RAR) may be responsible for reducing dynamic 
hyperinflation and increasing exercise tolerance. 
 The initial group selection for this study was based on RAR above or below 0.5 in at 
least one of the baseline exercise tests. However, it appears that control RAR is closer to 0.6 at 
rest and increases during exercise. Therefore, a resting or exercise RAR in the SEFV curve that 
is below that found in normal controls is likely sufficient to distinguish patients at risk for dynamic 
hyperinflation and exercise intolerance, and who will respond positively in these variables to 
bronchodilator treatment. Many COPD patients, as in this study, have an RAR >0.5 at rest, and 
while, in some, this tends to decrease with exercise, it may not fall below 0.5 before the patient 
reaches peak exercise. Nevertheless, an SEFV curve during expiration that is less convex than 
in normal subjects might indicate expiratory flow limitation. Therefore, irrespective of whether 
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the value of RAR falls below 0.5, the comparison between those who increase versus those 
who decrease the RAR during exercise seems to be a reasonable focus of future studies. 
A major limitation of this substudy is only having data for a portion of subjects tested in 
the parent study; hence, it was not powered for these analyses and this limits the 
generalizability of our findings. Despite this and the modest sample size, it was possible to 
observe statistically significant changes in RAR in response to placebo and tiotropium 
treatments. We believe these data help us to better understand the differences in responses to 
tiotropium in GOLD 1 and GOLD 2 groups in the main study whereby patients with concavity in 
the SEFV curve, rather than simply those with low FEV1, are more likely to respond positively to 
LAMA therapy.  Whether RAR of <0.5 is a useful demarcation point for predicting benefits of 
bronchodilator therapy (e.g., improved exercise tolerance, reduced hyperinflation) is not 
assessed. A separate study with a larger sample size is needed to understand if 0.5 or another 
RAR value would provide better discrimination. 
In summary, this study showed that subgroups of patients with different airway dynamics 
exist within GOLD classification groups. The RAR method can be used non-invasively to identify 
patients with concavity in the SEFV curve who represent a small proportion of GOLD 1 patients 
(1 out of 10 [10%] in this study population) but most GOLD 2 patients (6 out of 10 [60%] in the 
group we studied). Patients with low RAR at rest and during exercise demonstrate a significant 
reduction in expiratory flow limitation after tiotropium therapy, as well as in dynamic 
hyperinflation that is associated with increase in exercise endurance. Although it is true that 
there was some difference between FEV1 % predicted between the two groups, it appears that 
this type of analysis of the SEFV curves adds to the dynamics of airway function in that only 
those subjects improved their dynamic hyperinflation in response to tiotropium therapy who 
showed a decrease in RAR relative to the resting value. Future studies might seek to reproduce 
these findings in a larger population and in COPD patients with more severe obstruction.  
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Figure legends 
Fig. 1. Study design. In this analysis, the constant work rate exercise tests at Visit 3 and Visit 5 
DUHFRQVLGHUHGDVµEDVHOLQH¶WHVWVDQG9LVLWDQG9LVLWZHUHHLWKHUDIWHUSODFHERRUWLRWURSLXP
treatment phase. Reprinted with permission of the American Thoracic Society. Copyright © 
2017 American Thoracic Society. Casaburi R, Maltais F, Porszasz J, Albers F, Deng Q, Iqbal A, 
3DGHQ+$2¶'RQQHOO'(. 2014. Effects of tiotropium on hyperinflation and treadmill exercise 
tolerance in mild to moderate chronic obstructive pulmonary disease. Annals of the American 
Thoracic Society. Volume 11(9), Pages 1351Ǧ61. Annals of the American Thoracic Society is an 
official journal of the American Thoracic Society. 
Fig. 2. Derivation of the rectangular area ratio [RAR]5$5UHFWDQJXODUDUHDUDWLR9%cEEHQG-
H[SLUDWRU\IORZUDWH9%cmax, intra-breath peak flow rate. Reprinted from Respiratory Physiology & 
Neurobiology, Volume 234, Varga J, Casaburi R, Ma S, Hecht A, Hsia D, Somfay A, Porszasz J. 
Relation of concavity in the expiratory flow±volume loop to dynamic hyperinflation during 
exercise in COPD, Pages 79-84, 2016©, with permission from Elsevier. 
Fig. 3. Sample outputs from A: a subject showing no concavity and B: a subject showing 
concavity during exercise from IGOR procedures of breath-by-breath analysis. Traces from top 
to bottom: peak intrabreath flow rate (L/sec; 9%cmax), end-expiratory flow rate (L/sec; 9%cEE), 
rectangular area ratio (RAR), and instantaneous flow (L/sec); expiration upward, inspiration 
downward. The horizontal red line on the RAR panel represents RAR=0.5. The black lines are 
the result of an exponential smoothing; the corresponding RAR values were taken from this 
smooth line. 
Fig. 4. A: Rectangular area ratio (RAR) and B: inspiratory capacity (IC) in control, RARhigh group 
and RARlow group COPD patients during baseline constant work rate exercise tests as a 
function of ventilatory demand (minute ventilation/maximum voluntary ventilation [9%cE/MVV]). 
Data points are least square mean ± standard error of least square mean. For the control group 
data are from Visit 3; for COPD patients the points are the averages from Visit 3 and 5 (baseline 
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visits). In both panels, points from left to right: rest, warm-up, 4 and 2 min before peak exercise 
and peak exercise. A: RAR in controls, RARhigh group and RARlow gURXS&23'SDWLHQWVDVD
IXQFWLRQRIYHQWLODWRU\GHPDQG9%cE/MVV). Two-way repeated measures (RM) ANOVA p < 0.001, 
*: Pairwise multiple comparison by (Student±Neuman±Keuls test p < 0.01 for both controls and 
RARhigh group patients). B: Inspiratory capacity in controls, and RARhigh group and RARlow gURXS
&23'SDWLHQWVDVDIXQFWLRQRIYHQWLODWRU\GHPDQG9%cE/MVV). There are no statistical significant 
differences between groups by two-way RM ANOVA. MVV = forced expiratory volume in 1 s × 
40. 
Fig. 5. Change in inspiratory capacity (IC) in response to placebo or tiotropium treatment during 
constant work rate exercise in A: RARhigh group and B: RARlow COPD patients. Data points are 
least square mean ± standard error of least square mean. In the RARlow group, but not RARhigh 
group, the course of change in IC are significantly different between the two treatments (two-
way repeated measures ANOVA p < 0.01); *: denote significant difference according to pairwise 
comparison (Holm±âtGiNp < 0.05). Exercise phases: 1r: mean of three ICs during rest, w: 
warm up, p-4: 4 min before peak exercise, p-2: 2 min before peak exercise, r1: first minute into 
recovery. 
Fig. 6. Rectangular area ratio (RAR) at rest and during exercise in response to placebo and 
tiotropium treatment during constant work rate exercise in the A: RARhigh group and B: RARlow 
group COPD patients. Data points are least square mean ± standard error of least square 
mean. In the RARlow group, but not the RARhigh group, the RAR in the two treatment conditions 
are significantly different (two-way ANOVA p < 0.001). Multiple comparison did not reveal 
significances between any of the points during exercise. Exercise phases: 1r: mean of three ICs 
during rest, w: warm up, p-4: 4 min before peak exercise, p-2: 2 min before peak exercise, r1: 
first minute into recovery. 
Fig. 7. Correlation between inspiratory capacity (IC) % predicted and the rectangular area ratio 
(RAR) at peak exercise in the 7 RARlow patients. Data points are from all tests in these subjects, 
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including baseline and after both placebo and tiotropium treatment phase. (R2 = 0.43, p = 
0.0002, y0 = ±59, a = 260, SEE = 15.4). Predicted inspiratory capacity was calculated as total 
lung capacity predicted ± functional residual capacity predicted. For these reference values 
those of the Official Statement of the European Respiratory Society (Stocks and Quanjer, 1995) 
were used. 
 
 
 
 
Table 1 Subject characteristics. 
 
Control 
(n = 16) 
RARhigh group  
(RAR >0.5 in 
baseline 
studies) 
(n = 13) 
RARlow group 
5$5LQ
baseline 
studies) 
(n = 7) 
One-way 
ANOVA 
p-value  
Males/females  8/8 6/7 2/5  
GOLD 1/GOLD 2, n 0/0 9/4 1/6  
Age, years 60.4 ± 8.1 61.0 ± 7.0 60.1 ± 8.2  
FEV1, L (at baseline) 2.78 ± 0.65 2.15 ± 0.47a 1.60 ± 0.59a 0.001 
FEV1, % predictedf  103.2 ± 17.9 79.6 ± 10.1a 63.4 ± 14.0a,d 0.001 
FVC, L (at baseline) 3.39 ± 0.81 3.62 ± 0.85 3.06 ± 0.88 0.365 
FEV1/FVC 82.3 ± 4.2 59.9 ± 5.6a 51.7 ± 7.4a,d 0.001 
FEV1, L post placebo  2.03 ± 0.45 1.49 ± 0.70e  
FEV1, L post tiotropium  2.22 ± 0.54b 1.64 ± 0.71c  
 
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; RAR, rectangular area ratio.  
a
 p < 0.05 vs. control (Holm±âtGiNpost hoc test). 
b p = 0.004 vs. placebo (paired two-tailed t-test). 
c p = 0.038 vs. placebo (paired two-tailed t-test). 
d p = 0.003 vs. RARhigh (Holm±âtGiNpost hoc test). 
e
 p = 0.047 Student unpaired two-tailed t-test (RARhigh vs. RARlow). 
f
 Predicted values for FVC and FEV1 are from Quanjer et al. 
 







